微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 64.54% | 45.48% | -0.14% | 43/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 64.62% | 60.37% | 1.51% | 40/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 63.67% | 84.11% | 31.73% | 40/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 48.33% | 99.14% | 8.95% | 81/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 44.36% | 56.54% | 10.08% | 90/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 40.3% | 44.34% | 16.54% | 97/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 34.58% | 37.4% | 42.48% | 108/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 24.27% | -15.16% | -14.36% | 134/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 28.34% | -6.55% | 1.51% | 124/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 27.92% | -19.06% | 10.93% | 125/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 25.17% | -25.3% | -12.03% | 126/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 28.61% | -0.78% | -5.67% | 123/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 30.33% | 12.94% | -12.07% | 111/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 34.49% | 36.82% | 2.37% | 111/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 33.69% | 40.46% | 16.85% | 104/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 28.83% | -6.19% | 7.38% | 130/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 26.85% | -4.52% | 6.52% | 120/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 25.21% | 5.76% | 5.09% | 130/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 23.99% | -29.34% | -21.96% | 114/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 30.74% | 3.83% | 9.3% | 126/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 28.12% | -11.62% | 17.98% | 108/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 23.84% | -25.95% | -29.78% | 120/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 33.95% | -7.06% | 14.68% | 93/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 29.6% | -16.53% | -6.96% | 119/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 31.82% | -8.5% | -1.15% | 93/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 32.19% | -7.17% | -11.88% | 98/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 36.53% | 5.75% | 3% | 82/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 35.46% | 63.98% | 1.98% | 103/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 34.77% | 78.18% | 0.28% | 82/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 34.68% | 132.29% | 0.39% | 84/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 34.54% | 173.77% | 59.73% | 79/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 21.63% | 86.68% | 10.81% | 117/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 19.52% | 73.86% | 30.73% | 93/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 14.93% | 15.47% | 18.31% | 100/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 12.62% | -13.18% | 8.92% | 85/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 11.58% | -4.46% | 3.2% | 111/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 11.23% | -15.75% | -13.17% | 80/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 12.93% | -6.21% | -11.05% | 87/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 14.53% | -4.01% | 19.86% | 78/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 12.13% | -22.22% | -8.99% | 102/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 13.32% | -8.29% | -3.35% | 76/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 13.78% | -10.46% | -8.96% | 80/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 15.14% | 15.02% | -2.87% | 72/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |